問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2023-09-19

李日翔Lee, Jih-Hsiang
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

275Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李日翔

List

422Cases

2020-11-01 - 2025-01-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-02-28 - 2020-06-09

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2023-08-15 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-11-01 - 2026-01-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2016-10-20 - 2024-11-22

Phase I

Completed
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    FAZ053 & PDR001

Participate Sites
1Sites

Terminated1Sites

2021-04-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-10-03 - 2025-05-05

Phase I

Completed
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    DKY709

Participate Sites
1Sites

Recruiting1Sites

2017-10-11 - 2022-06-30

Phase II

Active
An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    LEE011 / Ribociclib (LDK378) / Ceritinib (HDM201)

Participate Sites
2Sites

Terminated2Sites

2022-03-01 - 2022-05-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2018-12-07 - 2024-12-31

Phase III

Completed
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)

  • Condition/Disease

    Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects

  • Test Drug

    ACZ885 (canakinumab)

Participate Sites
6Sites

Terminated6Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

江起陸
Taipei Veterans General Hospital

Division of Thoracic Medicine

1 21 22 23 24 25 43
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB